Three substituted pyridinecarboxylates were synthesized; (I) ethyl 2-bromo-4-4(fluorophenyl)-6-phenyl-3-pyridinecarboxylate, C20H15BrFNO2, (II) ethyl 4-(4-fluorophenyl)-2-(4-morpholinyl)-6-phenyl-3-pyridinecarboxylate, C24H23FN2O3, and (III) ethyl 4-(4-fluorophenyl)-6-phenyl-2-(1-piperidinyl)-3-pyridinecarboxylate, C25H25FN2O2. It was found that compound (I) belongs to the orthorhombic system with space group P212121, compound (II) to the monoclinic system with space group P21/c, and compound (III) to the monoclinic system with space group C2/c. The morpholine ring in (II) and piperidine ring in (III) have the shape of the distorted chair configuration. 1. Introduction Nicotinate (3-pyridinecarboxylate) esters represent an important class of heterocyclic compounds characterized by highly pronounced pharmacological and biological importance. Many publications have reported on numerous activities of various 3-pyridinecarboxylate esters as agrochemical fungicides [1, 2], herbicides [3, 4], A3 adenosine receptor antagonists [5], cholesteryl ester transfer protein inhibitors [6], blood circulation promoters, and anti-inflammatory agents [7, 8]. Pharmacological compositions containing nicotinate esters have been, also, appeared for using as antidandruff, anti-itching, and hair loss preventing [9, 10]. 2. Materials and Methods 2.1. Synthesis 2.1.1. Ethyl 2-Bromo-4-(4-fluorophenyl)-6-phenyl-3-pyridinecarboxylate (I) To a solution of ethyl 4-benzoyl-3-(4-fluorophenyl)-2-cyanobutyrate (10?mmol) in glacial acetic acid (20?mL), heated at 60–70°C, a solution of bromine (11?mmol) in glacial acetic acid (5?mL) was added dropwise while stirring, at such a rate maintaining the same temperature (15?min.). After complete addition, stirring was continued for 3?h at the same temperature. Then, the reaction mixture was stored at room temperature (25–30°C) overnight and poured into ice-cold water (200?mL). So, the separated solid was collected, washed with water, and crystallized from ethanol giving the corresponding compound (I) as colourless crystals. Reaction time 40?h; m.p. 134–136°C; yield 0.8?g (79%). Anal. for C20H15BrFNO2 (400.24): calcd. C 60.01, H 3.78, and N 3.50; found: C 60.22, H 3.70, and N 3.47, Figure 1. Figure 1: Scheme for synthesis of the investigated compounds. 2.1.2. Ethyl-4-(4-fluorophenyl)-2-(4-morpholinyl)-6-phenyl-3-pyridinecarboxylate (II) A mixture of (I) (2.5?mmol) and the corresponding secondary amine (10?mmol) in tetrahydrofuran (20?mL) was boiled under reflux for the appropriate time. The clear reaction mixture was evaporated till dryness under
References
[1]
D. G. Crosby, R. W. Emerson, T. C. Miller, D. P. Peterson, and L. P. Sharp, “Methods for Controlling a Pest Population,” Chemical Abstracts, vol. 134, p. 218309, 2001, (Summus Group, Ltd., USA) PCT Int. Appl. WO 01 19,185 (Cl. A01N29/00).
[2]
S. J. Bis, E. J. Canada, D. H. Cooper, et al., “2-methoxyimino-2-(pyridinyloxymethyl)phenyl acetamides with carboxylic acid derivatives on the pyridine ring as fungicides,” Chemical Abstracts, vol. 129, p. 161497, 1998, (Dow Agro-sciences LLC, USA) PCT Int. Appl. WO 98 33,772 (Cl. C07D213/79).
[3]
L. F. Lee, Y. L. L. Sing, and S. C. Wong, “Substituted pyridinecarboxylic acid derivatives as herbicides,” Chemical Abstracts, vol. 119, p. 249850, 1993, (Monsanto Co.) PCT Int. Appl. WO 93 11,112 (Cl. C07D213/80).
[4]
S. M. Auinbauh, L. F. Lee, and K. A. Van Sant, “Substituted 2,6-substituted pyridine herbicides,” Chemical Abstracts, vol. 118, p. 124407, 1992, (Monsanto Co.) PCT Int. Appl. WO 92 20,659 (Cl. C07D213/80).
[5]
K. A. Jacobson and A. H. Li, “A3 adenosine receptor antagonists,” Chemical Abstracts, vol. 132, p. 107876, 2000, (United States Dept. of Health and Human Services USA) PCT Int. Appl. WO 00 02,861 (Cl. C07D213/80).
[6]
L. F. Lee, K. C. Glenn, D. T. Connolly, et al., “Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity,” Chemical Abstracts, vol. 131, p. 157711, 1999, (G. D. Searle & Co., USA) PCT Int. Appl. WO 99 41,237 (Cl. C07D213/80).
[7]
E. Manabe, “Plaster having warm feeling,” Chemical Abstracts, vol. 130, p. 17225, 1999, (Taisho Pharmaceutical Co., Ltd., Japan) Jpn. Kokai Tokkyo Koho JP 10 298,066 [98 298,066] (Cl. A61K9/70).
[8]
G. E. Aldoma and S. E. Piatti, “Non-ulcerogenic analgesic/anti-inflammatory clonixin derivative,” Chemical Abstracts, vol. 128, p. 192558, 1998, (Handforth Investments Ltd.; Aldoma, Gustavo Enrique; Piatti, Susana Elida, UK) PCT Int. Appl. WO 98 07,701 (Cl. C07D213/80).
[9]
T. Ezure, N. Nakajima, H. Mori, and S. Kanayama, “Hair tonic,” Chemical Abstracts, vol. 134, p. 344333, 2001, (Shiseido Co., Ltd. Japan) Jpn. Kokai Tokkyo Koho JP 2001 122,739 (Cl. A61K7/06).
[10]
S. Takeda and M. Uemura, “Hair cosmetic,” Chemical Abstracts, vol. 130, p. 7255, 1998, (Shiseido Co., Ltd., Japan) Jpn. Kokai Tokkyo Koho JP 10 279,437 [98 279,437] (Cl. A61K7/06).
[11]
X-ray Crystallography Laboratory and National Research Center of Egypt (NRC), January 2014, http://www.xrdlab-nrc-eg.org/.
[12]
Enraf-Nonius, COLLECT, Nonius BV, Delft, The Netherlands, 1998.
[13]
Z. Otwinowski and W. Minor, “Processing of X-ray diffraction data collected in oscillation mode,” Methods in Enzymology, vol. 276, pp. 307–326, 1997.
[14]
M. S. Hayden and S. Ghosh, “Shared principles in NF-κB signaling,” Cell, vol. 132, no. 3, pp. 344–362, 2008.
[15]
S. Mackay, C. J. Gilmore, C. Edwards, N. Stewart, and K. Shankland, MaXus Computer Program for the Solution and Refinement of Crystal Structures, Bruker Nonius, Delft, The Netherlands, MacScience, Tokyo, Japan, University of Glasgow, Glasgow, UK, 1999.
[16]
L. J. Farrugia, “ORTEP-3 for windows—a version of ORTEP-III with a graphical user interface (GUI),” Journal of Applied Crystallography, vol. 30, no. 5, p. 565, 1997.
[17]
U. H. Patel, C. G. Dave, M. M. Jotani, and H. C. Shah, “Ethyl 3-amino-6-phenyl-4-tolylthieno[2,3-b]pyridine-2-carboxylate,” Acta Crystallographica C: Crystal Structure Communications, vol. 59, pp. m25–m26, 2003.
[18]
U. H. Patel, C. G. Dave, M. M. Jotani, and H. C. Shah, “1,3-Dimethyl-2-oxo-4,6-diphenyl-1,2,3,4-tetrahydropyridine-3-carbonitril e,” Acta Crystallographica C: Crystal Structure Communications, vol. 58, no. 3, pp. o191–o192, 2002.
[19]
S. Bhaskaran, S. Selvanayagam, D. Velmurugan et al., “N-(4a-Morpholino-2,3,4,4a,9,9a-hexahydro-1H-xanthen-9-yl)phenylamine,” Acta Crystallographica Section E: Structure Reports Online, vol. 59, no. 9, pp. o1301–o1303, 2003.
[20]
D. A. Parrish, J. R. Deschamps, F. Jiang, and N. T. Zaveri, “1-[1-(Decahydronaphthalen-1 -yl)piperidin-4-yl]indolin-2-one: one of a novel series of nociceptin receptor ligands,” Acta Crystallographica Section E: Structure Reports Online, vol. 60, no. 7, pp. o1253–o1254, 2004.